Technical Analysis for XLRN - Acceleron Pharma Inc.

Grade Last Price % Change Price Change
grade B 43.19 1.65% 0.70
XLRN closed up 1.65 percent on Tuesday, November 19, 2019, on 1.37 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Earnings due: Dec 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical XLRN trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Gapped Up Strength 0.00%
Fell Below 200 DMA Bearish 5.42%
Fell Below 50 DMA Bearish 5.42%
Down 3 Days in a Row Weakness 5.42%
Fell Below 20 DMA Bearish 0.45%
MACD Bearish Signal Line Cross Bearish 0.45%
MACD Bullish Signal Line Cross Bullish -3.25%

Older signals for XLRN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. The company develops sotatercept and ACE-536 that are in Phase II clinical trials to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes (MDS), and red blood cell disorders; and dalantercept, which is in Phase II clinical trials to inhibit blood vessel formation in tumors through the vascular endothelial growth factor pathway inhibitors. It has collaboration, license, and option agreement with Celgene Corporation. The company, formerly known as Phoenix Pharma, Inc., was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Biotechnology Cancer Life Sciences Rare Diseases Tumors Anemia Myelodysplastic Syndrome Celgene Myelodysplastic Syndromes Therapeutics For Cancer Ace 536
Is XLRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 56.91
52 Week Low 37.01
Average Volume 297,834
200-Day Moving Average 42.7702
50-Day Moving Average 42.5403
20-Day Moving Average 43.6543
10-Day Moving Average 42.8085
Average True Range 1.9425
ADX 17.02
+DI 29.8969
-DI 28.3527
Chandelier Exit (Long, 3 ATRs ) 41.9675
Chandelier Exit (Short, 3 ATRs ) 45.9775
Upper Bollinger Band 47.5234
Lower Bollinger Band 39.7852
Percent B (%b) 0.44
BandWidth 17.726089
MACD Line 0.099
MACD Signal Line 0.3353
MACD Histogram -0.2363
Fundamentals Value
Market Cap 1.67 Billion
Num Shares 38.6 Million
EPS -2.49
Price-to-Earnings (P/E) Ratio -17.35
Price-to-Sales 108.28
Price-to-Book 7.53
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.58
Resistance 3 (R3) 45.70 45.02 45.18
Resistance 2 (R2) 45.02 44.42 44.96 45.04
Resistance 1 (R1) 44.11 44.04 44.57 43.99 44.91
Pivot Point 43.43 43.43 43.66 43.37 43.43
Support 1 (S1) 42.52 42.83 42.98 42.40 41.47
Support 2 (S2) 41.84 42.45 41.78 41.34
Support 3 (S3) 40.93 41.84 41.20
Support 4 (S4) 40.81